Overall, these results identify key targets to inhibit heterologous donor-reactive memory CD8+ T cell activation within the allograft microenvironment and improve survival of allografts subjected to longer CIS times prior to transplant, such as deceased-donor grafts. Here, CD8A is linked to in situ carcinoma.